# Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis.

> **NCT02792231** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 955 (actual)

## Conditions studied

- Relapsing Multiple Scelrosis

## Interventions

- **DRUG:** Ofatumumab subcutaneous injection
- **DRUG:** Teriflunomide-matching placebo capsules
- **DRUG:** Teriflunomide capsule
- **DRUG:** Matching placebo of ofatumumab subcutaneous injections

## Key facts

- **NCT ID:** NCT02792231
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08-26
- **Primary completion:** 2019-07-10
- **Final completion:** 2020-10-22
- **Target enrollment:** 955 (ACTUAL)
- **Last updated:** 2021-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02792231

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02792231, "Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis.". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT02792231. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*